Pioglitazone (Actos)

Pioglitazone (Actos) is a diabetes drug. It works by improving a patient’s response to the hormone insulin. It is manufactured by Takeda and Eli Lilly & Co. Ltd.

In HIV-positive patients, pioglitazone can improve the insulin resistance, high blood pressure and blood fat alterations that can occur as a side-effect of HIV treatment.1

Side-effects include upset stomach and liver toxicity.

References

  1. Gavrila A et al. Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial. Clin Infect Dis 40: 745-749, 2005

Up a level
Back to contents
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.